Loading...
Market
Which company's stock will perform the best by the end of 2024: Roche (RHHBY), Novo Nordisk, or Eli Lilly?
3
Resolution / Starting Odds
Roche (RHHBY) performs the best • 25%
Novo Nordisk performs the best • 25%
Eli Lilly performs the best • 25%
All perform similarly • 25%
Stock market data from financial news platforms like Bloomberg or Reuters
Story
Roche Announces Positive Phase I Results for CT-996 Obesity Drug, Shares Rise 7.5%
Jul 17, 2024, 10:22 AM
Roche has announced positive early results from a Phase I clinical trial of its oral GLP-1 receptor agonist, CT-996, aimed at treating obesity. The trial demonstrated meaningful weight reduction in patients with obesity, showing a placebo-adjusted mean weight loss of 6.1% within four weeks. The drug, which can potentially be dosed without regard to meal timing, is seen as a promising candidate for oral weight maintenance therapy following weight loss induced by injectables. Following the announcement on Wednesday, Roche's shares (RHHBY, ROG.CH) rose by 7.5% in premarket trading. Conversely, shares of competitors Novo Nordisk and Eli Lilly fell by 3.1% and 3.4% respectively. The drug was acquired as part of Roche's $3.1 billion takeover of Carmot.
View original story
Similar markets
Eli Lilly > 20% increase • 25%
Eli Lilly 10-20% increase • 25%
Novo Nordisk 10-20% increase • 25%
Novo Nordisk > 20% increase • 25%
Novo Nordisk outperforms • 25%
Eli Lilly outperforms • 25%
Both perform equally • 25%
Both underperform • 25%
Roche outperforms Merck • 25%
Merck outperforms Roche • 25%
Both perform similarly • 25%
Both underperform the market • 25%
Outperform significantly • 25%
Outperform slightly • 25%
Underperform • 25%
Match performance • 25%
Outperforms all major competitors • 25%
Performs similarly to major competitors • 25%
Underperforms compared to some competitors • 25%
Underperforms all major competitors • 25%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
VKTX outperforms both • 25%
VKTX outperforms NVO but not LLY • 25%
VKTX outperforms LLY but not NVO • 25%
VKTX underperforms both • 25%
Novo Nordisk • 25%
Sanofi • 25%
Eli Lilly • 25%
Other • 25%